INZY - Inozyme Pharma stock price slides 8% on pricing $60M offering

2023-07-28 05:01:44 ET

Clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, Inozyme Pharma ( NASDAQ: INZY ) priced an underwritten public offering of 12.5M shares at a price of $4.80 per share.

Gross proceeds of ~$60M.

Underwriters' have an option to purchase up to an additional 1,875,000 shares.

The offering is expected to close on or about August 1, 2023.

The stock price was down 8% during pre-market hours on Friday.

For further details see: